Microbot Medical Partners with Sanmina to Scale LIBERTY System Manufacturing and Reduce Costs
MBOT sits 17% above its 52-week low of $1.6.
Summary
Microbot Medical has partnered with Sanmina Corporation to expand manufacturing capacity for its LIBERTY Endovascular Robotic System, aiming to meet rising demand and reduce production costs.
Key Events · M&A and Partnerships · MBOT
-
Strategic Manufacturing Agreement
Microbot Medical Inc. has entered into a Letter of Agreement with Sanmina Corporation, a global integrated manufacturing solutions provider, to manufacture its LIBERTY Endovascular Robotic System.
-
Expanded Production Capacity
The agreement is designed to expand manufacturing capacity to meet expected demand from existing and new accounts for the LIBERTY System, which has seen increasing adoption and regulatory clearances.
-
Cost Reduction Strategy
The partnership supports the company's cost reduction strategy, aiming to improve operating efficiencies, lower costs, and expand gross margins.
-
Diversified Manufacturing
Sanmina will serve as a second manufacturing site, diversifying the company's production capabilities and providing potential for global scaling.
Analysis · MBOT · Industrial Applications And Services
This agreement with Sanmina Corporation is a critical operational step for Microbot Medical. As the company's LIBERTY Endovascular Robotic System gains market traction and regulatory approvals, securing a global manufacturing partner ensures it can meet increasing demand. The partnership also aims to improve operating efficiencies and lower production costs, which is vital for improving gross margins and moving towards profitability, especially given the company's reported Q1 losses and cash burn.
At the time of this filing, MBOT was trading at $1.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $125.6M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.